A recent study has demonstrated that a precision medicine approach improves treatment selection for patients with soft tissue sarcomas (STS) in a clinical setting. Published in npj Precision Oncology in March 2025, the research findings support using data-driven and phenotypic screening approaches to treat STS. The study was conducted by researchers from the Agency for Science, Technology and Research (A*STAR), National Cancer Centre Singapore (NCCS) and National University of Singapore (NUS), in collaboration with biotech company, KYAN Technologies.
This article was originally published on MedicalXpress.com
